Poviztra vs Wegovy: Comparison Guide

Poviztra vs Wegovy: Comparison Guide

Navigating the world of weight management medications can feel overwhelming, especially as new options become available. Two names you might hear are Wegovy and the more recent Poviztra. Both are injectable medications designed to help with chronic weight management, and both are based on semaglutide. Poviztra is a second brand of Wegovy from Novo Nordisk, so it is the same medicine sold under a different name.

This guide offers a clear, practical comparison to help you understand the key similarities and differences between them. The goal is to provide you with knowledge to have a more informed conversation with your doctor. Consult your healthcare provider before starting any medication.

Understanding the Science: GLP-1

To understand how Wegovy and Poviztra work, it helps to know about a class of medications called incretin mimetics. These drugs mimic the action of natural hormones in your body that are released after you eat.

The most well-known of these is glucagon-like peptide-1 (GLP-1). This hormone sends signals to your brain that you feel full, slows down how quickly your stomach empties, and helps regulate blood sugar.

Both Wegovy and Poviztra are based on semaglutide, which works through the GLP-1 pathway. That means this comparison is less about two different hormone mechanisms and more about product branding, market availability, pricing, and access in different regions.

A Closer Look at Wegovy (semaglutide)

Wegovy has been a prominent option for chronic weight management for several years. Its active ingredient is semaglutide.

How Wegovy Works

Wegovy is a GLP-1 receptor agonist. This means it specifically mimics the GLP-1 hormone. By activating these receptors in the body, it helps reduce appetite and food intake, leading to weight loss. It is intended to be used alongside a reduced-calorie diet and increased physical activity.

Administration and Dosing

Wegovy is administered as a once-weekly injection using a pre-filled, single-use pen. Treatment typically starts with a low dose of 0.25 mg once a week. This dose is gradually increased every four weeks over a period of 16 weeks to reach the usual maintenance dose of 2.4 mg. In some markets, including the US (approved March 2026), a higher 7.2 mg dose can be used for some people who have tolerated 2.4 mg; this is your prescriber's decision. This slow increase, known as titration, helps the body adjust to the medication and reduces the likelihood of gastrointestinal side effects.

Key Clinical Findings

Major clinical trials have shown that Wegovy is an effective tool for weight management. In the STEP 1 trial in adults with obesity or overweight without diabetes, people taking semaglutide 2.4 mg with lifestyle support lost an average of 14.9% of their body weight over 68 weeks, compared with 2.4% on placebo.

A Closer Look at Poviztra (semaglutide)

Poviztra is a second brand of Wegovy (semaglutide) from Novo Nordisk. It is distributed by Eurofarma in Brazil (from October 2025) and by Emcure Pharmaceuticals in India (launched December 2025). Its active ingredient is semaglutide, and it is not a generic or biosimilar.

How Poviztra Works

Poviztra works through the same GLP-1 receptor agonist mechanism as Wegovy. In practical terms, that means it helps reduce appetite, increases feelings of fullness, and supports weight loss when paired with diet and exercise.

Administration and Dosing

Like Wegovy, Poviztra is a once-weekly injection that patients can administer themselves. In India it was launched in the same five strengths as Wegovy (0.25 mg, 0.5 mg, 1 mg, 1.7 mg and a 2.4 mg maintenance dose), and it follows the same dose-escalation schedule. This helps manage potential side effects as the body gets used to the medication.

What the Research Suggests

Because Poviztra is a second brand of Wegovy, the clinical evidence relevant to it is the Wegovy (semaglutide 2.4 mg) evidence used for chronic weight management. The key questions for patients are typically formulation, prescriber guidance, availability, and cost rather than a different hormone mechanism.

Side-by-Side Comparison: Poviztra vs. Wegovy

While both medications share the goal of aiding in weight loss, their differences are important to understand.

Active Ingredient and Mechanism

• Wegovy: The active ingredient is semaglutide, a GLP-1 receptor agonist.
• Poviztra: The active ingredient is also semaglutide, which means it works through the same GLP-1 pathway.

Common Side Effects

Because both medications affect the GLP-1 receptor and impact the digestive system, they share a very similar side effect profile. The most commonly reported side effects for both include:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal pain

These side effects are typically mild to moderate and often decrease over time as the body adjusts. The gradual dose-escalation schedule is designed specifically to help manage these effects.

When to get urgent help: contact a doctor or emergency services straight away for severe stomach pain that does not go away, with or without vomiting and sometimes spreading to the back (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of the skin or eyes (possible gallbladder problems); vomiting or diarrhoea that stops you keeping fluids down (risk of dehydration and kidney injury); or swelling of the face or throat or trouble breathing (possible severe allergic reaction). Semaglutide should not be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2. Tell your doctor if you are pregnant or planning a pregnancy, if you have diabetic eye disease, or if you have surgery or sedation planned. If you also take insulin or a sulfonylurea, your doctor may need to adjust those medicines to lower the risk of low blood sugar.

Efficacy in Weight Management

Both Wegovy and Poviztra are intended to support chronic weight management when combined with diet and exercise. Because both are semaglutide products, expected effectiveness is grounded in semaglutide evidence rather than in two different mechanisms. Individual results can still vary significantly.

Who Is a Candidate for These Medications?

Both Wegovy and Poviztra are generally indicated for adults with a certain body mass index (BMI)—typically 30 or greater, or 27 or greater with at least one weight-related condition such as high blood pressure, dyslipidemia, or obstructive sleep apnea. Exact approved indications can vary by country and product label. For example, the US Wegovy label also covers reducing the risk of heart attack and stroke in adults with heart disease and obesity or overweight, adolescents aged 12 and over with obesity, and a type of fatty liver disease (MASH).

The decision about whether one of these medications is appropriate is a medical one. A healthcare provider will evaluate your overall health, medical history, and weight management goals to determine if you are a suitable candidate.

Making an Informed Decision

Choosing a weight management medication is a significant decision that should be made in partnership with your healthcare team. While Wegovy and Poviztra may differ in branding, local availability, and pricing, they are the same semaglutide medicine from the same company, not two different treatment strategies.

The "better" option is the one that is right for you. This depends on your personal health profile, local access, affordability, and your clinician’s assessment. The most successful weight management plans involve medication as one tool within a comprehensive strategy that includes nutrition, physical activity, and behavioral support.

Your journey is unique, and the right medical support can make all the difference. Consult your healthcare provider before starting any medication.

Sources

• Wegovy US prescribing information (Novo Nordisk, revised June 2026): https://www.novo-pi.com/wegovy.pdf
• https://www.ema.europa.eu/en/documents/product-information/wegovy-epar-product-information_en.pdf
• STEP 1 trial (Wilding et al., NEJM 2021): https://pubmed.ncbi.nlm.nih.gov/33567185/
• Eurofarma press release on Poviztra and Extensior in Brazil (October 2025): https://www.eurofarma.cl/lang/en/press-room/eurofarma-is-the-first-brazilian-pharmaceutical-company-to-launch-biological-injectable-semaglutide-treatments-for-obesity-and-diabetes
• BioSpectrum India: Novo Nordisk India partners with Emcure Pharma to commercialise Poviztra in India (November 2025): https://biospectrumindia.com/news/16/26901/novo-nordisk-india-partners-with-emcure-pharma-to-commercialise-poviztra-in-india.html
• The Week (PTI): Emcure Pharma launches weight loss drug (December 2025): https://www.theweek.in/wire-updates/business/2025/12/22/dcm40-biz-emcure-drug-launch.html
• https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity